Zydus Lifesciences (ZYDUSLIFE) investor relations material

Executive summary

• Achieved strong double-digit revenue and profit growth for FY 2026, surpassing expectations and delivering record operating profit and margins, with audited results approved by the Board on May 19, 2026.

• Growth was broad-based across U.S., India, international markets, and consumer wellness, with successful integration of acquisitions and expansion into new business verticals.

• Strategic focus on specialty, biosimilars, MedTech, and digital transformation to drive future growth.

• Board approved a buyback of up to Rs. 11,000 mn at a 16% premium to the closing share price as of May 18, 2026.

• Final dividend of Re. 1 per equity share recommended, subject to shareholder approval at the AGM on August 11, 2026.

Financial highlights

• Consolidated FY 2026 revenue reached INR 271.5 billion, up 17% year-over-year; Q4 revenue at INR 75.9 billion, up 16% YoY and 11% QoQ.

• FY 2026 EBITDA margin improved to 31.2% (+80 bps YoY); Q4 EBITDA margin at 33.7% (+110 bps YoY, +720 bps QoQ).

• FY 2026 EBITDA grew 20% to INR 84.8 billion; net profit (adjusted) up 15% to INR 54.6 billion; consolidated net profit attributable to owners for FY26 was ₹50,400 million, up from ₹45,255 million in FY25.

• Net debt to EBITDA at 0.5x as of March 31, 2026; net debt stood at Rs. 43,050 mn as of March 31, 2026.

• Basic and diluted EPS (consolidated) for FY26 was ₹50.09, compared to ₹44.97 in FY25.

Outlook and guidance

• FY 2027 revenue expected to grow in high teens; North America to see single-digit growth, India to outperform market by 200-400 bps, international markets to sustain strong momentum.

• EBITDA margin guidance for FY 2027 is above 24%, factoring in R&D at 8% of revenue and investments in specialty launches.

• CapEx for FY 2027 projected at INR 1,500 crore; quarterly depreciation around INR 550 crore.

• Continued focus on expanding branded and specialty portfolios, with investments in R&D and new launches across geographies.

• Dividend payout of Re. 1 per share recommended for FY26, pending AGM approval.